

Nordic–Baltic Conference in Pharmacovigilance 2026

2 June, Stockholm



Program

Conference moderators: *Sara Maxe*, Maxe Pharma Consulting and *Patricia Jimenez Vasquez*, MSD

09.00 Registration

09.30 **Welcome and practical information**
Läkemedelsakademin and moderators

09.45 **Keynote lecture:**
Real Life impact of drug safety work
Felix Arellano, Roche

Session: AI in Pharmacovigilance from authority and industry perspective

10.15 **AI Tools for PV at the Swedish Medical Products Agency**
Luise Dürlich, Swedish Medical Products Agency

10.35 **Applications of AI in PV: from Transactional tasks in Case handling and Periodic reporting to Multimodal Predictive Clinical Safety models during Drug Development**
Magnus Nord, AstraZeneca

10.55 Coffee break

11.25 **Trusted use of AI in Pharmacovigilance**
Vijay Kara, GSK

11.45 **Discussion**
Luise Dürlich, Swedish Medical Products Agency; *Magnus Nord*, AstraZeneca; *Vijay Kara*, GSK; *Julia Appelskog*, CSL

12.05– Lunch break
13.15

Session: The PV role in small vs big company – global environment vs affiliate – how to bridge similarities and benefit from the differences

13.15 **From PV Macroformat to Microformat: Leveraging Differences, Building on Similarities**
Karin Kempe, Karo Healthcare

13.35 **Global Vision Meets Local Reality: Pharmacovigilance in Small Companies, Big Pharma, and Affiliates**
Julia Appelskog, CSL

13.55 **Discussion**
Karin Kempe, Karo Healthcare; *Julia Appelskog*, CSL; *Sanna Laine*, Sanna Laine Pharma Consulting and *Patricia Jimenez Vasquez*, MSD

Session: To transform EMA decisions into local practices

14.15 **Risk minimisation materials – from PRAC – discussion to national implementation – a regulatory perspective**
Ulla Wändel Liminga, MPA Sweden and PRAC

14.35 Coffee break

15.05 **Effectiveness of risk minimisation measures to prevent pregnancy exposure: an example of mycophenolate use in women of childbearing age in Estonia**
Katrin Kurvits, State Agency of Medicines, Estonia

15.20 **The national agency's experience in approving digital communication tools in addition to the regular channels used for dissemination of educational materials – additional risk minimisation measures**
Lina Masionienė, State Medicines Control Agency of Lithuania

15.35 **Discussion**
All session speakers

Session: News from Regulators & a Future outlook

15.55 **Local novelty in pharmacovigilance**
Liene Luce, State Agency of Medicines, Latvia

16.10 **Farmasto – a single access point to reliable high-quality medicines information**
Johanna Seppänen, Finnish Medicines Agency

16.25 **Discussion Future of PV**
Felix Arellano, Roche; *Ulla Wändel Liminga*, MPA Sweden and PRAC; *Julia Appelskog*, CSL; *Johanna Seppänen*, Fimea; *Liene Luce*, State Agency of Medicines, Latvia

16.50– **Closing**
17.00 *Moderators*